Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies

Table 2 Randomized clinical trial study characteristics

Study	Number of patients	Mean age (years)	Outcome measure^a	CYC treatment	Placebo/alternative treatment	Corticosteroid	Length of follow-up (months)
Hoyles and colleagues [10]	45	55	FVC, 80.1 ± 10.3	Intravenous, 600 mg/m² monthly	Placebo	Prednisone 20 mg alternate days	12
			DLCO, 52.9 ± 1.6
Nadashkevich and colleagues [11]	60	38 to 36	FVC, 90.3 ± 1.9	Oral, 2 mg/kg/day monthly	AZA 2.5 mg/kg	Prednisolone 15 mg/day	12
			DLCO, 83.5 ± 1.6
Tashkin and colleagues [1]	158	47.9 ± 1.0	FVC, 67.6 ± 1.3	Oral, 1 mg/kg/day	Placebo	None	12
			DLCO, 47.2 ± 1.6

Data presented as mean ± standard deviation. AZA, azathioprine; CYC, cyclophosphamide; DLCO, diffusing capacity for carbon monoxide; FVC, forced vital capacity. ^aPercentage predicted value at baseline.

ISSN: 1478-6362